The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system
- 1 May 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 87 (1), 196-198
- https://doi.org/10.1111/j.1365-2141.1994.tb04892.x
Abstract
Agranulocytosis was observed in a 63-year-old patient with myelodysplasia 6 weeks after commencing chelation with the oral iron chelator deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one, L1) at a daily dose of 79 mg/kg. Using a liquid culture system no difference was observed when L1 toxicity to normal and patient myelopoiesis was compared (IC50: 150 v 172 microM respectively). L1 was found to be less toxic than desferrioxamine (DFX) (IC50: 150 v 9 microM respectively) to normal myelopoiesis. Delayed addition of iron to myeloid cultures containing an inhibitory concentration of L1 or DFX was associated with reversal of chelator-induced inhibition of myelopoiesis up to 6 h but not after 24 h. Further studies are needed to determine the incidence and elucidate the pathogenesis of agranulocytosis associated with L1 therapy.Keywords
This publication has 5 references indexed in Scilit:
- Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitroEuropean Journal of Haematology, 1994
- Agranulocytosis in a Patient with Thalassaemia major during Treatment with the Oral Iron Chelator, 1,2-Dimethyl-3-Hydroxypyrid-4-0neActa Haematologica, 1993
- Clinical Experience of Clozapine†-Induced Neutropenia in the UKDrug Safety, 1992
- Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4- one iron chelators in overloaded and nonoverloaded miceBlood, 1991
- Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-onesInorganica Chimica Acta, 1987